Novel inhibitors of bacterial virulence: Development of 5,6-dihydrobenzo[h]quinazolin-4(3H)-ones for the inhibition of group A streptococcal streptokinase expression

ACS Citation

Yestrepsky, B.D.; Yuanxi Xu; Breen, M.E.; Yuanxi Xu; Rajeswaran, W.G.; Ryu, J.G.; Sorenson, R.J.; Tsume, Y.; Wilson, M.W.; Wenpeng Zhang; Duxin Sun; Hongmin Sun; Larsen, S.D. Novel inhibitors of bacterial virulence: Development of 5,6-dihydrobenzo[h]quinazolin-4(3H)-ones for the inhibition of group A streptococcal streptokinase expression. Bioorg. Med. Chem., 2013, 21, 7, 1880-1897.

Abstract

Resistance to antibiotics is an increasingly dire threat to human health that warrants the development of new modes of treating infection. We recently identified 1 (CCG-2979) as an inhibitor of the expression of streptokinase, a critical virulence factor in Group A Streptococcus that endows blood-borne bacteria with fibrinolytic capabilities. In this report, we describe the synthesis and biological evaluation of a series of novel 5,6-dihydrobenzo[h]quinazolin-4(3H)-one analogs of 1 undertaken with the goal of improving the modest potency of the lead. In addition to achieving an over 35-fold increase in potency, we identified structural modifications that improve the solubility and metabolic stability of the scaffold. The efficacy of two new compounds 12c (CCG-203592) and 12k (CCG-205363) against biofilm formation in Staphylococcus aureus represents a promising additional mode of action for this novel class of compounds.

Source Name

Bioorganic & Medicinal Chemistry

Publication Date

4-1-2013

Volume

21

Issue

7

Page(s)

1880-1897

Document Type

Citation

Citation Type

Article

Link to Google Scholar

Share

COinS